Tag: GCP compliance

Site Network Partnerships vs Standalone Sites: Operational Pros and Cons Site Network Partnerships vs Standalone Sites: Operational Pros and Cons Site selection and qualification are pivotal components in the success of clinical trials. The decision to participate in a multi-site network or remain a standalone site has significant implications for clinical research management. This guide…

Read More “Site Network Partnerships vs Standalone Sites: Operational Pros and Cons” »

Regulatory and Ethics Considerations in Site Qualification Strategies Regulatory and Ethics Considerations in Site Qualification Strategies The successful execution of a clinical trial hinges on the meticulous selection and qualification of trial sites. In the context of regulatory compliance and ethical standards, professionals in clinical operations, regulatory affairs, and medical affairs face a myriad of…

Read More “Regulatory and Ethics Considerations in Site Qualification Strategies” »

Remote and Hybrid Site Qualification Models After the Pandemic Remote and Hybrid Site Qualification Models After the Pandemic The COVID-19 pandemic has significantly altered the landscape of clinical trials, necessitating a reevaluation of site selection and qualification processes. As clinical operations, regulatory affairs, and medical affairs professionals seek to adapt to these changes, developing effective…

Read More “Remote and Hybrid Site Qualification Models After the Pandemic” »

Aligning Site Selection With Diversity, Equity and Inclusion Goals Aligning Site Selection With Diversity, Equity and Inclusion Goals In the evolving landscape of clinical research, the necessity for diversity, equity, and inclusion (DEI) has garnered significant attention. Site selection is a crucial aspect of clinical trials that can either promote or hinder the achievement of…

Read More “Aligning Site Selection With Diversity, Equity and Inclusion Goals” »

Inspection-Ready Documentation of Site Selection and Qualification Rationale Inspection-Ready Documentation of Site Selection and Qualification Rationale In clinical research, achieving regulatory compliance is imperative for ensuring the credibility of study results and safeguarding participant welfare. One critical component that directs this process is the comprehensive documentation of site selection and qualification rationale. This step-by-step guide…

Read More “Inspection-Ready Documentation of Site Selection and Qualification Rationale” »

Using Real-World Data and Epidemiology to Prioritize Clinical Trial Sites Using Real-World Data and Epidemiology to Prioritize Clinical Trial Sites In the rapidly evolving landscape of clinical research, the necessity for strategic site selection is paramount. Utilizing real-world data (RWD) and epidemiological insights becomes increasingly critical in ensuring the success of clinical trials. This comprehensive…

Read More “Using Real-World Data and Epidemiology to Prioritize Clinical Trial Sites” »

Central vs Local Site Selection Approaches for Global Sponsors and CROs Central vs Local Site Selection Approaches for Global Sponsors and CROs In the evolving landscape of clinical research, global sponsors and Contract Research Organizations (CROs) face significant challenges and decisions regarding site selection. Selecting the right clinical trial sites is crucial for efficient study…

Read More “Central vs Local Site Selection Approaches for Global Sponsors and CROs” »

Qualification Visit Checklists That Predict Recruitment and Quality Qualification Visit Checklists That Predict Recruitment and Quality In the realm of clinical trials, particularly within the framework of gilead clinical trials, the recruitment of suitable participants is pivotal to successful outcomes. To ensure adherence to ICH-GCP guidelines and regulatory requirements from bodies such as the FDA,…

Read More “Qualification Visit Checklists That Predict Recruitment and Quality” »

De-Risking New or Naïve Sites Without Slowing Study Timelines In the rapidly evolving landscape of clinical trials, the urgency to bring new treatments to market frequently intersects with the necessity of meticulous site selection and qualification. This tutorial provides a comprehensive step-by-step guide for clinical operations, regulatory affairs, and medical affairs professionals focused on de-risking…

Read More “De-Risking New or Naïve Sites Without Slowing Study Timelines” »